FMP
NASDAQ
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
0.81 USD
-0.0199 (-2.46%)
Valuation Date:
Apr 26, 2024 4:00 PM
Share Price on Valuation Date
$0.81
Stock Beta
0.528
Shares Outstanding
2473740